Skip to main content
. 2021 Feb 16;10(2):411. doi: 10.3390/cells10020411

Figure 4.

Figure 4

The frequencies of CD19+CD24hiCD38hi Breg cells (A) and IL-10 concentration (B) in PBMCs of RRMM patients before and after 5 cycles of daratumumab treatment. (A) Flow cytometry analysis demonstrated significantly increased expression of Bregs in RRMM patients before the treatment with daratumumab compared to samples obtained after 5 cycles of the therapy (p = 0.0003). (B) ELISA test results showed no significant differences of IL-10 levels in RRMM patients after daratumumab treatment (p = 0.1297). The representative dot plots of Breg subpopulations showing CD19+CD24hiCD38hi Breg population before (C) and after daratumumab treatment (D). Cells were stained with surface-stained with anti-CD19 Pe-Cy7, anti-CD24-APC, anti-CD38-FITC, and intracellularly with IL10-PE antibodies.